$CRIS

Why Did Curis (CRIS) Stock Soar After Hours? - Curis (NASDAQ:CRIS)

Curis Inc. (NASDAQ:CRIS) shares rose 8.51% to $0.46 after hours Wednesday after the company confirmed its previously approved reverse stock split will take effect Thursday at 5:00 p.m. ET, with split-adjusted trading starting Jul. 6. Shareholders approved a 1-for-5 to 1-for-25 split to help regain Nasdaq’s $1 bid compliance.

Original reporting
Published Jul 2, 2026, 9:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 9:22 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Did Curis (CRIS) Stock Soar After Hours? - Curis (NASDAQ:CRIS) — source image
Decision brief

The 30-second read

$CRISNeutralMed
01

Why it matters

The confirmed effective time and the start of split-adjusted trading explain the after-hours surge and set the next mechanical catalyst for liquidity/price normalization.

02

Market read

This is a time-specific corporate action confirmation that can drive short-term trading volatility and technical positioning.

03

What to watch

Traders may overreact to the percentage move; the key is split-adjusted trading mechanics and Nasdaq compliance optics, not new fundamentals.

Relevance 6/10Novelty 6/10Timing: After-hours today; split effective 5:00 p.m. ET Thursday and split-adjusted trading begins Jul. 6.

Background

Curis previously received approval for a reverse stock split to address Nasdaq’s $1.00 minimum bid price rule.

Company-level read

Ticker impact

$CRISNeutralMedium confidence
Context

Curis shares jumped after-hours as the company confirmed its previously approved reverse stock split would take effect Thursday.

Expected impact

Near-term volatility likely around the split-adjusted trading start (Jul. 6), with price action driven more by mechanics than fundamentals.

Evidence & confidence

The article cites an SEC filing confirming the split effective time and that trading continues under CRIS, but provides no new operating/financial catalyst.

Market effects

Limited sector read-through; this is a microcap compliance/corporate-action event rather than biotech-specific news.

No clear regional spillover beyond US microcap/Nasdaq compliance dynamics.

Low; reverse-split mechanics are company-specific and not tied to global biotech developments.

Counterpoint

A reverse split can temporarily lift the tape/price level, but it does not reduce underlying business risk or dilution/financing needs.

Key entities

  • Curis, Inc.

    NASDAQ-listed biotech confirming its approved reverse stock split takes effect Thursday and begins split-adjusted trading Jul. 6.

  • Nasdaq $1.00 minimum bid price rule

    Compliance threshold Curis is targeting via the reverse split.

Related articles

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.

$CRISMedAI 8/10

Curis stock jumps 11% on positive emavusertib trial data By Investing.com

Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.

$RTXMedAI 8/10

U.S. Army Awards Collins $427M for CH-47 Chinook Modernization

The U.S. Army plans to spend over $1B to modernize its CH-47 Chinook fleet. According to RTX, Collins Aerospace won up to $472M for open-architecture avionics upgrades. Separately, Boeing received over $870M for up to 60 CH-47F Block II variants, with 24 on order, and future A2X tech for automated approaches.

$BAMed

Irish widow receives €25m compensation after husband's death

An Irish widow, Naoise Connolly Ryan, received about $29 million (€25 million) in damages after a 2019 Ethiopian Airlines crash killed her husband, who worked for the UN. The suit was filed in a US court against Boeing, which has admitted failures and that anti-stall software was implicated in prior crashes. A Chicago jury awarded damages in the case.